Vaccines and therapeutics for immunocompromised patients with COVID-19

S Shoham, C Batista, YB Amor, O Ergonul… - …, 2023 - thelancet.com
The COVID-19 pandemic has disproportionately impacted immunocompromised patients.
This diverse group is at increased risk for impaired vaccine responses, progression to …

An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines

F Bayani, NS Hashkavaei, S Arjmand, S Rezaei… - Progress in Biophysics …, 2023 - Elsevier
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus that
has caused the recent coronavirus disease (COVID-19) global pandemic. The current …

[HTML][HTML] Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants

Q Wang, S Iketani, Z Li, L Liu, Y Guo, Y Huang… - Cell, 2023 - cell.com
The BQ and XBB subvariants of SARS-CoV-2 Omicron are now rapidly expanding, possibly
due to altered antibody evasion properties deriving from their additional spike mutations …

Resistance of Omicron subvariants BA. 2.75. 2, BA. 4.6, and BQ. 1.1 to neutralizing antibodies

D Planas, T Bruel, I Staropoli… - Nature …, 2023 - nature.com
Convergent evolution of SARS-CoV-2 Omicron BA. 2, BA. 4, and BA. 5 lineages has led to
the emergence of several new subvariants, including BA. 2.75. 2, BA. 4.6. and BQ. 1.1. The …

Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents

Y Cao, F Jian, Z Zhang, A Yisimayi, X Hao, L Bao… - Cell reports, 2022 - cell.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages have
escaped most receptor-binding domain (RBD)-targeting therapeutic neutralizing antibodies …

AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults

Y Cai, S Diallo, K Rosenthal, K Ren, DJ Flores… - Science Translational …, 2024 - science.org
The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
resulted in variants that can escape neutralization by therapeutic antibodies. Here, we …

Challenges and developments in universal vaccine design against SARS-CoV-2 variants

F Zhao, X Zai, Z Zhang, J Xu, W Chen - npj Vaccines, 2022 - nature.com
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had
become a global concern because of its unexpectedly high pathogenicity and …

Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN. 1 sublineages

Q Wang, IA Mellis, J Ho, A Bowen… - Emerging Microbes & …, 2024 - Taylor & Francis
The recently dominant SARS-CoV-2 Omicron JN. 1 has evolved into multiple sublineages,
with recurrent spike mutations R346T, F456L, and T572I, some of which exhibit growth …

Antibodies to watch in 2023

H Kaplon, S Crescioli, A Chenoweth, J Visweswaraiah… - MAbs, 2023 - Taylor & Francis
In this 14th installment of the annual Antibodies to Watch article series, we discuss key
events in commercial monoclonal antibody therapeutics development that occurred in 2022 …

Identification of a highly conserved neutralizing epitope within the RBD region of diverse SARS-CoV-2 variants

Y Wang, A Yan, D Song, M Duan, C Dong… - Nature …, 2024 - nature.com
The constant emergence of SARS-CoV-2 variants continues to impair the efficacy of existing
neutralizing antibodies, especially XBB. 1.5 and EG. 5, which showed exceptional immune …